$维立志博-B(09_老虎社区_美港股上老虎

艳阳高照天

07-28

$维立志博-B(09887)$中国TCE第一股的稀缺性还是值钱的，首日开盘翻倍，当前TCE疗法的研发主要集中在血液肿瘤领域，而维立志博在更具市场前景的实体瘤治疗领域建立了先发优势，值得这个溢价

维立志博-B首日近翻倍！能否继续持有？

维立志博-B于7月25日在港交所上市，盘中一度升近130%，收涨超91%，总市值近130亿港元。【大家还看好该股后续涨势吗？你会继续持有吗？】

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":461476082049688,"tweetId":"461476082049688","gmtCreate":1753688311348,"gmtModify":1753688458207,"author":{"id":9000000000000219,"idStr":"9000000000000219","authorId":9000000000000219,"authorIdStr":"9000000000000219","name":"艳阳高照天","avatar":"https://static.tigerbbs.com/ab7a887f7d1ab09c9b3f648ad7c56ad4","vip":8,"userType":8,"introduction":"运营账号","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":16,"starInvestorFlag":false},"themes":[{"themeId":"ea79df3ca11c411d857d85195aaee090","categoryId":"7ba93224048e4975aa9a5a60d7f2353b","name":"维立志博-B首日近翻倍！能否继续持有？","type":0,"rnLink":"https://laohu8.com/RN?name=RNTheme&page=/theme/detail&rndata={\"themeId\":ea79df3ca11c411d857d85195aaee090}&rnconfig={\"headerBarHidden\": true}","description":"维立志博-B于7月25日在港交所上市，盘中一度升近130%，收涨超91%，总市值近130亿港元。【大家还看好该股后续涨势吗？你会继续持有吗？】","image":"https://static.tigerbbs.com/6239c374134a0434b9f014259b5179ad"}],"images":[],"coverImages":[],"html":"<html><head></head><body> <a data-mention-id=\"09887\" rel=\"noopener noreferrer\" class=\"teditor-mention\" data-mention-name=\"维立志博-B\" target=\"_blank\" href=\"https://laohu8.com/S/09887\">$维立志博-B(09887)$</a>中国TCE第一股的稀缺性还是值钱的，首日开盘翻倍，当前TCE疗法的研发主要集中在血液肿瘤领域，而维立志博在更具市场前景的实体瘤治疗领域建立了先发优势，值得这个溢价</body></html>","htmlText":"<html><head></head><body> <a data-mention-id=\"09887\" rel=\"noopener noreferrer\" class=\"teditor-mention\" data-mention-name=\"维立志博-B\" target=\"_blank\" href=\"https://laohu8.com/S/09887\">$维立志博-B(09887)$</a>中国TCE第一股的稀缺性还是值钱的，首日开盘翻倍，当前TCE疗法的研发主要集中在血液肿瘤领域，而维立志博在更具市场前景的实体瘤治疗领域建立了先发优势，值得这个溢价</body></html>","text":"$维立志博-B(09887)$中国TCE第一股的稀缺性还是值钱的，首日开盘翻倍，当前TCE疗法的研发主要集中在血液肿瘤领域，而维立志博在更具市场前景的实体瘤治疗领域建立了先发优势，值得这个溢价","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/461476082049688","repostId":0,"isVote":1,"tweetType":1,"viewCount":1238,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["09887"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":true,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":171,"optionInvolvedFlag":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/461476082049688"}